UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become First Huntington’s Treatment

UniQure plans a first quarter 2026 FDA submission for AMT-130 as a treatment for Huntington’s disease. This gene therapy delivers microRNA designed to silence the mutated gene that produces a protein driving this disorder, which so far has no FDA-approved therapies. The post UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become…

Read More

Tracking State Actions on Vaccine Policy and Access

With recent federal actions to curtail vaccine access, many states have announced actions intended to maintain broader access. This issue brief provides a snapshot of this rapidly changing landscape, tracking which states have instituted changes in response to or in anticipation of administration policy changes.

Read More